MEDICRIME anti-counterfeiting convention adopted
This article was originally published in RAJ Devices
Executive Summary
Discussions are under way concerning the date of the opening for signature of the MEDICRIME convention, the first international criminal law instrument that criminalises the counterfeiting of medicines and medical devices and also the manufacture and supply of medical products that are unauthorised or do not comply with security requirements1-3.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.